When was Cel-Sci founded?

Cel-Sci was founded in 1983 and raised its 1st funding round 26 years after it was founded.

Where is Cel-Sci located?

Cel-Sci is headquartered in Vienna, United States. It is registered at Vienna, Virginia.

How many employees does Cel-Sci have?

As of May 31, 2026, the latest employee count at Cel-Sci is 18.

Is Cel-Sci a funded company?

Cel-Sci is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 20, 2009.

When was the latest funding round of Cel-Sci?

Cel-Sci's latest funding was a $***** Post IPO round on Jun 30, 2020, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.14B in funding in 2026 to date.

What is the annual revenue of Cel-Sci?

Annual revenue of Cel-Sci is between $1 and $1M as on Jul 10, 2018

Where does Cel-Sci rank among its competitors?

Cel-Sci ranks 24th amongst 213 active competitors, of which 69 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Alpha Tau Medical, which secured $36.9M in Apr, 2025.

Who are the top competitors of Cel-Sci?

Cel-Sci's top competitors include RefleXion, ImmunityBio and Alpha Tau Medical. Among them, Alpha Tau Medical secured the most recent funding round in April, 2025.

Cel-Sci - 2026 Company Profile, Funding, Competitors & Financials

Cel-Sci is a public company based in Vienna (United States), founded in 1983. It operates as a Developer of immunotherapy products for the treatment of cancer and infectious diseases. Cel-Sci has raised an undisclosed amount in funding. The company has 213 active competitors, including 69 funded and 38 that have exited. Its top competitors include companies like RefleXion, ImmunityBio and Alpha Tau Medical.

Company Details

Developer of immunotherapy products for the treatment of cancer and infectious diseases. The lead candidate therapy, Multikine is developed for the treatment of certain head and neck cancers, and peri-anal warts or cervical dysplasia in human immunodeficiency virus (HIV), and human papillomavirus (HPV). The company has L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology has two investigational therapies for the treatment of pandemic influenza and CEL-2000, a vaccine product for the treatment of rheumatoid arthritis.

Website: cel-sci.com
Social
Registered Address: Vienna, Virginia

Key Metrics

Founded Year

1983

Location

Vienna, United States

Stage

Public

Latest Funding Round

Post IPO, Jun 30, 2020, $*****

Investors

Alpha Capital Partners & 8 more

Ranked

24^th among 213 active competitors

Annual Revenue

$1 - $1M as on Jul 10, 2018

Employee Count

18 as on May 31, 2026

Similar Companies

RefleXion & 268 more

Exit Details

Public

View Cel-Sci's full profile

Cel-Sci is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CEL-SCI CORPORATION CIN: 840916344 , United States, Active	Dec 26, 999	-	53 (As on Dec 31, 2024)	-
CEL SCI CORP CIN: 725363 , United States, Active		$1 - $1M (As on Jul 10, 2018)	-	-

Cel-Sci got listed on Jan 01, 1987.

Click here to take a look at Cel-Sci's IPO in detail

Cel-Sci has raised funding over 7 rounds. Its first funding round was on Aug 20, 2009. Cel-Sci has 9 institutional investors.

Here is the list of recent funding rounds of Cel-Sci:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2020	7930826	Post IPO	6441140	8763055	8984329	4360966
Oct 23, 2018	7725639	Post IPO	4733640	4014936	8999232	6887446
Sep 14, 2018	6082120	Post IPO	4341817	2772166	7006814	1562027

Access funding benchmarks and valuations. Sign up today!

View details of Cel-Sci's funding rounds and investors

Cel-Sci's employee count trend

Cel-Sci has 18 employees as of May 26. Here is Cel-Sci's employee count trend over the years:

Uncover Cel-Sci's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cel-Sci include RefleXion, ImmunityBio and Alpha Tau Medical. Here is the list of Top 10 competitors of Cel-Sci, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	RefleXion 2009, Hayward (United States), Series F	Provider of biology-guided radiotherapy system	$542M	The Rise Fund, PSP Investments & 24 others	70/100
2nd	ImmunityBio 2014, El Segundo (United States), Public	Developer of peptide-based vaccines for immunotherapy	$169M	Oberland Capital, NantWorks & 1 others	67/100
3rd	Alpha Tau Medical 2015, Tel Aviv (Israel), Public	Developer of radiotherapy technique for the treatment of solid cancer tumors	$55M	Shavit Capital, OurCrowd & 15 others	66/100
4th	SetPoint Medical 2006, Santa Clarita (United States), Series F	Developer of implantable neuromodulation devices for inflammatory diseases	$388M	Medtronic, Flare Capital Partners & 32 others	64/100
5th	Osivax 2017, Lyon (France), Series B	Developer of vaccines against constantly mutating pathogens	$42.2M	EIC Fund, Noshaq & 10 others	64/100
6th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Yunfeng Capital & 7 others	63/100
7th	SpyBiotech 2017, Oxford (United Kingdom), Series A	Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology	$39M	Braavos, Oxford Science Enterprises & 6 others	61/100
8th	Mevion Medical Systems 2004, Littleton (United States), Series F	Proton therapy systems for oncology	$500M	ProQuest Investments, Yuan Ming Capital & 9 others	60/100
9th	Affinivax 2013, Cambridge (United States), Acquired	Developer of technology-based conjugate vaccines against infectious diseases	$359M	Gates, Foresite Capital & 14 others	59/100
10th	CStone Pharma 2016, Shanghai (China), Public	Developing and licensing novel drugs for diseases including cancer and autoimmune diseases	$410M	GIC, Boyu Capital & 14 others	59/100
24th	Cel-Sci 1983, Vienna (United States), Public	Developer of immunotherapy products for the treatment of cancer and infectious diseases	-	Alpha Capital Partners, Midsummer Capital ... & 7 others	53/100